Breakthrough T1D Joins Diabetes Leaders at the American Diabetes Association 85th Scientific Sessions to Highlight Research Advancements
NEW YORK, June 24, 2025 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, gathered with researchers, diabetes professionals, and other leaders in T1D at the American Diabetes Association's (ADA) 85th Scientific Sessions, where Breakthrough T1D scientists, clinicians, and Breakthrough T1D-funded researchers presented research results and led crucial conversations that will improve the lives of people with T1D while driving toward cures for the disease.
Held June 20-23 in Chicago, Illinois, the ADA Scientific Sessions is one of the largest diabetes conferences in the world. Breakthrough T1D-supported research has been highlighted at this annual event since the organization started funding research in the 1970s.
"The American Diabetes Association Scientific Sessions highlights the latest advancements in type 1 diabetes research and treatments from the brightest minds in the field and demonstrates the tremendous progress being made on the path to cures for the disease," said Breakthrough T1D CEO Aaron Kowalski, Ph.D. "While we know that the burden of living with type 1 diabetes is substantial, I'm encouraged each year by the collective innovation and commitment presented at the conference. As the leader in type 1 diabetes research, Breakthrough T1D is proud to fund and support so many of the scientists and experts who are driving the critical research needed to accelerate breakthroughs that will improve the lives of those living with type 1 diabetes and one day allow us to walk away from the disease."
Breakthrough T1D leaders participated in several presentations and panel discussions, presenting important data and perspectives about Breakthrough T1D's mission priority areas and the research advancements that benefit those with T1D. Breakthrough T1D Chief Scientific Officer Sanjoy Dutta, Ph.D., spoke about cell therapies, Breakthrough T1D Research Director Jonathan Rosen, Ph.D., led a session on cardiovascular complications in T1D, Breakthrough T1D Vice President of Medical Affairs, Anastasia Albanese-O'Neill, Ph.D., APRN, CDCES, participated in a panel about women in diabetes professions, and Breakthrough T1D Research Scientist, Courtney Ackeifi, Ph.D., presented Breakthrough T1D's perspective at the Symposium ADJUnct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) Trial Outcomes. Other Breakthrough T1D leaders presented at poster sessions and events surrounding the conference that covered health policy issues in T1D, ways to include the patient voice and expand clinical trial participation, the promise of cell therapies, the importance of the Special Diabetes Program, a federally funded program that provides $160 million annually for T1D research, and more.
Key research highlights from the sessions include:
Vertex Pharmaceuticals shared additional results on the phase I/II clinical trial of zimislecel, also known as VX-880, their manufactured islet cell therapy that requires immunosuppression. All 12 participants with T1D who received the full dose of cells eliminated severe hypoglycemic events and had an HbA1c hemoglobin level of less than 7%, meeting the trial's primary endpoints. These individuals achieved more than 70% of time in the target glucose range within 6 months and improved further at the 365-day mark. Notably, 10 of the 12 participants (83%) achieved insulin therapy independence and were not using exogenous insulin at day 365. Breakthrough T1D's support for Doug Melton, whose proprietary lab-created beta cells are now being advanced by Vertex, goes back decades.
Sana Biotechnology gave an update on the individual with T1D who received a transplant of deceased donor islets that were gene-edited with Sana's Hypoimmune (HIP) technology. HIP technology makes the cells immune-evasive, meaning they are not destroyed by the body's immune system. This therapy does not require the use of immunosuppressives. According to the six-month data, the transplanted islets are safe and well-tolerated, remain undetected by the immune system, and continue to make insulin in response to high blood glucose levels. Sana is working toward applying HIP technology to manufactured islets as a scalable treatment for T1D.
A presentation on ADJUnct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial outcomes demonstrated that the use of semaglutide, a GLP-1 receptor agonist, as an adjunctive, non-insulin therapy helped individuals living with T1D and obesity and using automated insulin delivery systems to keep their blood glucose levels in the target range and achieve weight loss. Those in the study reported no incidences of diabetic ketoacidosis or hypoglycemia, and the drug was well-tolerated and safe. These results add to the body of evidence on the safety and efficacy of semaglutide for people with T1D.
More information about T1D research shared at ADA and Breakthrough T1D-funded research and presentations can be found on Breakthrough T1D's website.
About Breakthrough T1D, Formerly JDRF As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition.
About Type 1 Diabetes (T1D) T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.
Contact:Casey Fielder509-651-0087media@breakthroughT1D.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/breakthrough-t1d-joins-diabetes-leaders-at-the-american-diabetes-association-85th-scientific-sessions-to-highlight-research-advancements-302490112.html
SOURCE Breakthrough T1D, Formerly JDRF
Error al recuperar los datos
Inicia sesión para acceder a tu cartera de valores
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
28 minutes ago
- Forbes
Targeting The Heart With AI
Cardiologist doctor examine patient heart functions and blood vessel on virtual interface. Medical ... More technology and healthcare treatment to diagnose heart disorder and disease of cardiovascular system. It's one thing to talk about what AI will do in healthcare – they use cases and applications that will change the face of that field. It's something else to describe how this will happen – how the body's systems interact with the technology in ways that can, frankly, be pretty amazing. Our bodies are immensely complex – very sophisticated machines with literally dozens of functional systems put together in a unified whole. That's not to mention the immense structure of the human brain, which Marvin Minsky famously characterized as hundreds of machines working together in his Society of the Mind book, as well as his legacy of work at MIT. Complex Systems in Human Biology Just take the heart – the body's largest muscle, and responsible for keeping us alive by pumping blood through the body in particular ways. With its multiple chambers, its complex system of veins and arteries, its electrical impulses and more, the heart is in some ways enigmatic and difficult for clinicians to work on. The gold standard for cardiac evaluation is the EKG; at least, it has been for decades. But what if AI and other technologies could find new ways of getting cardiac information, and new ways of diagnosing and processing it for patient care? The Equipment of Cardiology Recently, my colleague, Daniela Rus, director of the MIT CSAIL lab, interviewed SandboxAQ CEO Jack Hidary at Imagination in Action this spring. They talked about specifically that: how quantum technology and artificial intelligence could be used to innovate heart care. Prior to that, though, Hidary talked about other medical use cases, pointing out, for example, that 85% of clinical trials fail, and that specific strategies with AI can save enormous amounts of time and money in looking at how proteins bind to receptors, or other outcomes. A Quick Glossary Prior to going into the specifics of new AI heart treatment Hidary referenced CUDA (Compute Unified Device Architecture) which is a parallel computing platform created by NVIDIA that allows developers to use some of the company's hardware for general-purpose and scientific computing. That's going to be relevant here. He also talks about tensors, in aid of explaining how teams can 'put quantum on GPUs' - he also mentioned quantum sensors, which are new ways to gather information by using quantum science for precision in data handling. That's where this theory on cardiology care comes in. Replacing the EKG The EKG assesses the electric field of the heart. A new quantum and AI method, Hidary suggested, would instead focus on the magnetic field of the heart. This could come through the body in a very direct and full way, in order to provide better and more detailed data. Think of it as a type of lossless signal compression that will deliver better data to cardiac assessment. 'This is something that is melding AI and quantum together,' he said. 'You can't do one without the other.' Here's how he described the process: 'Your skin conductance is very indirectly related to your heart,' Hidary said. 'Those wires (in the new system) are not on your heart itself. They're on your skin, but the magnetic field comes through the cavity of the body, undisturbed, unperturbed, intact in 360 degrees, (in data) around us that is a beautiful, pristine, high-density information view of the heart, unlike the EKG, which is very indirect and often has many false positives and many, many false negatives.' In listening to Hidary talk, you get the idea that we may be on the verge of revolutionary new kinds of heart treatments that rely on the intersection of quantum and AI to see what's really happening inside of a person's body. More on Heart Care This resource from Campanile Cardiology talks about changing care from reactive to proactive, and using pattern recognition and predictive power for early detection. The author also covers efforts to figure out the heart's 'real age' or biological age based on conditions like plaque buildup. Or you can take this set of predictions from JACC, notwithstanding the medical-ese in which they're written: · AI-enabled technologies are increasingly integrated into cardiovascular practice and investigation. · Over the next decade, we envision an AI-propelled future in which the cardiovascular diagnostic and therapeutic landscape will effectively leverage multimodal data at the point of care. · Innovations in biomedical discovery and cardiovascular research are also set to make the future of cardiovascular care more personalized, precise, and effective. · The path to this future requires equitable and regulated adoption that prioritizes fairness, equity, safety, and partnerships with innovators as well as our communities and society. In any case, it looks like we are close to unlocking new types of healthcare with the technologies at our disposal. And these are brand new. Five years ago, ten years ago, nobody was writing about these things, because they didn't functionally exist. What we've discovered is a new expanse of uncharted waters. That's going to keep us busy for quite a while.
Yahoo
42 minutes ago
- Yahoo
Kansas City Chiefs OL Trey Smith reflects on health issues before the 2021 NFL Draft
During the latest episode of New Heights, Travis Kelce and his brother Jason welcomed Kansas City Chiefs offensive guard Trey Smith. The Pro Bowl offensive lineman opened up about his battle with blood clots at Tennessee. "One week in conditioning, we were doing half-gassers, and I passed out. I had never passed out. I couldn't breathe well," said Smith, "I lost 13 pounds in a day. I remember talking to our team doctor, 'Hey, you guys gotta run more tests on me; I feel terrible. And he's like, 'We're gonna do a blood draw, just go ahead and go to class." Advertisement After starting at left tackle during his sophomore season, Tennessee's medical staff discovered blood clots in Smith's lungs and ruled him out indefinitely. The issue was identified in February 2018, before the start of spring practice. "They rush me to the hospital and figure out that I have blood clots in both sides of my lungs," said Smith, "So that was sort of one of those moments where it's like, man, can I still play football? Like, what does this mean? And pretty much, I was working with the doctors for five months. (I had to go on) blood thinners." Smith started all ten games in his last collegiate season, earning first-team All-SEC honors for the Volunteers. "So it was a crazy experience. But in my junior year, I was able to play the entire season. Decided to stay at Tennessee, "said Smith, "I made a promise to my deceased mom, Dorsetta Smith, that I would get my degree and play in the NFL one day. So I kept my promise." Advertisement Smith was drafted in the sixth round of the 2021 NFL Draft and has emerged as one of the best offensive linemen in the league. This article originally appeared on Chiefs Wire: Chiefs' Trey Smith reflects on health issues before the 2021 NFL Draft
Yahoo
43 minutes ago
- Yahoo
As a family court judge, I know chronic absenteeism is a public health crisis
Every day across Kentucky, thousands of students fail to show up for school. Some miss a few days a month. Others are absent for weeks at a time. When the final tallies are made, many will have missed more than 10% of the school year. This pattern, known as chronic absenteeism, is quietly eroding the futures of our children — and we cannot afford to ignore it. Across the United States, over 8 million students are chronically absent each year. In districts serving our most vulnerable populations, that number is even higher. And while many still think of absenteeism as a discipline issue or a matter of personal responsibility, I see something else entirely. As a family court judge, I've learned that chronic absenteeism is often the first visible sign that something much deeper is wrong in a child's life. It may be illness, untreated trauma, housing insecurity or caregiving burdens at home. It may be depression, anxiety or a simple lack of transportation. These are not just educational challenges — they are public health concerns. That's why we need to reframe how we think about absenteeism. When we treat it like a public health crisis — because that's exactly what it is — we open the door to early intervention, stronger support systems and meaningful, long-term solutions. Opinion | Louisville has abandoned its most vulnerable youth while pretending to care Far too often, students who are chronically absent fall behind academically and never catch up. This disconnect from school can lead to disengagement from peers, lower self-esteem and in many cases, contact with the juvenile justice system. When children drop out, the consequences extend far beyond the classroom — they echo through our economy, our public safety systems, and our communities for generations. And we must recognize that this crisis is not hitting all children equally. Chronic absenteeism disproportionately affects Black, Latino, Indigenous, low-income and disabled students. These disparities are rooted in inequities in health care access, housing, nutrition and neighborhood safety. If we are serious about addressing absenteeism, we must be equally serious about addressing the systems that allow those inequities to persist. The good news? We can change this. Opinion | JCPS chose new superintendent Brian Yearwood the right way School-based health centers, mobile mental health units, trauma-informed classrooms and strong family engagement strategies have all proven effective. Judicial diversion programs that prioritize rehabilitation over punishment can break cycles before they begin. Community-based partnerships can ensure students are surrounded by the support they need — not just to get to school, but to thrive while they're there. But to make real progress, we must stop treating absenteeism as someone else's problem. It belongs to all of us. Schools alone cannot fix it. This is a call to action for public health officials, judges, educators, faith leaders and families alike. We must ask different questions. Instead of 'Why isn't this child in school?' we need to ask, 'What's happening in this child's life that's keeping them from showing up?' That shift — from blame to understanding — can change everything. I've seen what happens when we wait too long. But I've also seen what's possible when we act early — with compassion, coordination and commitment. Every child deserves a chance to be present, to be supported and to succeed. Let's not wait until they're in my courtroom to figure that out. Agree or disagree? Submit a letter to the editor. Derwin L. Webb serves as chief judge of Family Court in Jefferson County, Kentucky. He is a former Division I athlete and the first African American male family court judge elected in the Commonwealth of Kentucky. This article originally appeared on Louisville Courier Journal: KY chronic school absences reveal a public health concern | Opinion
